U/S-guided Continuous Quadratus Lumborum Block III in Percutaneous Nephrolithotomy

Surgery Clinical Trial

Official title:

Ultrasound-guided Continuous Quadratus Lumborum Block III for Postoperative Analgesia in Percutaneous Nephrolithotomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04800302
• Other study ID #: USGCQLBIIIPCNL
• Status: Completed
• Phase: N/A
• Start date: June 10, 2021
• Est. completion date: June 28, 2022

Study information

• Verified date: July 2022
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Percutaneous nephrolithotomy (PCNL) is considered to be the first choice and a more conservative procedure than open stone surgery. Not only postoperative pain related to dilatation of the renal capsule and parenchymal tract, but also patient's discomfort & nephrostomy tube-related stress are reported to delay recovery time and increase the complication rates. This study is designed to provide postoperative analgesia by using ultrasound-guided continuous Quadratus Lumborum Block (QLB) III in patients undergoing PCNL and to assess pain scores & side effects with less opioids consumption.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: June 28, 2022
• Est. primary completion date: June 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• ASA I-II.

• Scheduled for percutaneous nephrolithotomy (PCNL).

Exclusion Criteria:

• Patient refusal.

• Coagulation disorders.

• Skin lesions or infection at site of needle insertion.

• Known allergy to local anesthetics or opioids.

• Patients suffering from neurological or mental disease.

• Procedure turned into open stone surgery.

• Failure of identification by U/S.

• Urinary tract malignancies.

• Opioid consumption 48 hours before the operation.

Related Conditions & MeSH terms

• Analgesia
• Kidney Calculi
• Nephrolithiasis
• Renal Stone
• Surgery

Intervention

Procedure:
• Continous Quadratum Lumborum Block III
Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum & psoas major muscles with ultrasound guidance.
• Single dose Quadratum Lumborum Block III
Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
• Intra-venous Morphine
Intra-venous Morphine [0.1 mg/kg] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.

Locations

Country	Name	City	State
Egypt	Cairo University Hospitals	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Nazmy Edward Seif

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Morphine consumption.	Total dose of Morphine (measured in mg) given intra-venously to the patient post-operatively.	24 hours